Taken together, these results show that high-dose MNU treatment increases the number of TILs in KP tumors, causes an increased and sustained expression of PD-L1 in the tumor microenvironment, and improves the response to anti-PD1 checkpoint inhibitor. This evidence concerns the gene CD274 and neoplasm.